________________________________________________________________________________________________________________________
CDMO services to improve product development and speed to market, or some need to fill capability gaps like biomaterial procurement or regulatory submission. With our extensive portfolio of biomaterials, capabilities, and technical expertise, we help our customers to build scalable solutions in global markets.
“ While we have business metrics like yield attainment, cycle times and on-time delivery to help us run efficiently, our top priority is always to align the decisions we make with the benefits they will have on a patient or for the clinician. Every process we design, every validation we run, and every record we complete is done with a patient-centric mindset. Knowing that we improve people’ s lives every day is a privilege. In the allograft side of the business, for instance, we process human donated tissue; these are gifts of life, and we take that responsibility very seriously.”
This patient-centric approach also extends to Evergen’ s R & D operations.“ Innovation always begins with the patients and the procedures,” Kevin states.“ We listen to our OEM customers to learn about their challenges and the unique clinical needs of the patients, and once we understand the problem, we identify the best biomaterial in the ideal form for each procedure. This collaborative nature is the defining strength that enables us to develop customized solutions. We bring development and manufacturing together early in the processes, leveraging our expertise in technical R & D, biomaterials, and manufacturing processes. We also apply risk management and quality by design principles to ensure innovations aren’ t just new ideas but products that consistently and reliably perform.”
▼ Kevin Breeden, COO
250